Open Access 2.0

Open Access 2.0 © Grant Faint/Getty Images The nautilus: where - and how - OA will actually work By Joseph J. Esposito Related Articles The nautilus model of scientific publishing OA, OK? The debate over open access to the scientific literature appears to be moving onto a new phase. Many continue to argue one side or the other of a binary choice: Either all research publishing should be open access, or only traditional publishing can maintain

Written byJoseph J. Esposito
| 13 min read

Register for free to listen to this article
Listen with Speechify
0:00
13:00
Share

By Joseph J. Esposito

The nautilus model of scientific publishing

OA, OK?

The debate over open access to the scientific literature appears to be moving onto a new phase. Many continue to argue one side or the other of a binary choice: Either all research publishing should be open access, or only traditional publishing can maintain peer review and editorial integrity. Others, however, have moved beyond that false dichotomy, instead increasingly seeing various hybrid models emerging and new, often complex, business arrangements.

Partly this is a product of the apparent inability of open-access ventures to produce economically sustainable models. It is unclear whether BioMed Central, a privately held sister company of The Scientist, has broken even, and the Public Library of Science tax return from the fiscal year ending September 30, 2006, the most recent publicly available, indicates that the organization lost $1.4 million on $5 million in revenue. Even ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies